Genentech's Herceptin Could Provide Q3 Upside
13th Sep 2005, 17:30 GMT
Bear Stearns maintained an outperform rating on Genentech and said breast cancer drug Herceptin could provide substantial upside to the biotech firm's Q3 results.
Latest news from Bio-Technology News from myHealthcareNews.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress